Latest news articles

Added 17 days ago Drug news

EC approves Darzalex + lenalidomide + dexamethasone for newly diagnosed multiple myeloma.- Genmab

Genmab announced that the European Commission (EC) has granted marketing authorization for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone...

Added 1 month ago Drug news

CHMP recommends approval of Darzalex + lenalidomide and dexamethasone in multiple myeloma.- Genmab

Genmab announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued...

Added 2 months ago Drug news

FDA approval of Darzalex + bortezomib + thalidomide and dexamethasone for multiple myeloma patients who are eligible for autologous stem cell transplant. Janssen Biotech

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Darzalex (daratumumab) in combination with bortezomib (Velcade),...

Search all news articles for Multiple myeloma

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more


Myeloma: diagnosis and management

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over.

Added 3 years ago

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and...

Added 3 years ago

Guidelines for the use of imaging in the management of patients with myeloma

The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging...

Added 1 year ago

Search all guidelines for Multiple myeloma

Journal articles

Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.

Background: Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT...

Added 8 months ago

Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation.

Although peripheral blood stem cells (PBSC) have worldwide become the predominant source of progenitor cells for hematopoietic stem cell transplantation (HSCT), debate about their role compared with bone marrow (BM)...

Added 8 months ago

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

This article summarizes the scientific review of the application leading to regulatory approval in the European Union.

Added 1 year ago

Search all journal articles for Multiple myeloma

Clinical trials

Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Added 1 year ago

Study of lenalidomide and dexamethasone with or without pembrolizumab (MK-3475) in participants with newly diagnosed treatment naive multiple myeloma (MK-3475-185/KEYNOTE-185)

The purpose of this study is to compare the efficacy of adding pembrolizumab to lenalidomide and low dose dexamethasone in participants with treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (auto-SCT).

Added 2 years ago

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

The purpose of this study is to compare the efficacy of adding pembrolizumab to pomalidomide and low dose dexamethasone in participants with refractory or relapsed multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment.

Added 2 years ago

Search all clinical trials for Multiple myeloma